Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin

被引:65
作者
Kovacs, MJ [1 ]
Keeney, M [1 ]
MacKinnon, K [1 ]
Boyle, E [1 ]
机构
[1] London Hlth Sci Ctr, London, ON, Canada
来源
CLINICAL AND LABORATORY HAEMATOLOGY | 1999年 / 21卷 / 01期
关键词
heparin; dalteparin; monitoring; anti-Xa levels; thrombosis;
D O I
10.1046/j.1365-2257.1999.00183.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this study we compare three chromogenic methods (IL-Heparin, Stachrom Heparin and Heparin Sigma) on two different instruments (ACL300+ and AMAX CS190) for patients on dalteparin (n = 41), a low molecular weight heparin or unfractionated heparin (n = 50). For dalteparin the mean anti-Xa levels for IL-Heparin, Stachrom Heparin and Heparin Sigma were 0.27, 0.30 and 0.21U/ml, respectively, while for heparin they were 0.52, 0.55 and 0.41U/ml, respectively. To test for instrument specific effects, IL-Heparin and Stachrom Heparin were repeated on both instruments on 42 patients receiving unfractionated heparin. For IL-Heparin the mean anti-Xa levels on the AMAX CS190 and ACL300+ were 0.51 and 0.59 U/ml, respectively, while for Stachrom Heparin they were 0.55 and 0.67 anti-Xa U/ml. We conclude that different chromogenic anti-Xa methods do not give equivalent anti-Xa levels for the same samples. Moreover, the differences are clinically significant. This is not explained entirely by instrumentation effects,Recommended therapeutic ranges may need to be method and instrument specific.
引用
收藏
页码:55 / 60
页数:6
相关论文
共 14 条
[1]  
ABILDGAARD U, 1990, HAEMOSTASIS, V20, P193
[2]  
BONEU B, 1994, THROMB HAEMOSTASIS, V72, P330
[3]   ESTABLISHING A THERAPEUTIC RANGE FOR HEPARIN-THERAPY [J].
BRILLEDWARDS, P ;
GINSBERG, JS ;
JOHNSTON, M ;
HIRSH, J .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (02) :104-109
[4]  
DIGNAC M, 1993, NOUV REV FR HEMATOL, V35, P545
[5]   Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X [J].
Hardy, JF ;
Belisle, S ;
Robitaille, D ;
Perrault, J ;
Roy, M ;
Gagnon, L .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 112 (01) :154-161
[6]   THE INTERNATIONAL NORMALIZED RATIO - A GUIDE TO UNDERSTANDING AND CORRECTING ITS PROBLEMS [J].
HIRSH, J ;
POLLER, L .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (03) :282-288
[7]   CONTINUOUS INTRAVENOUS HEPARIN COMPARED WITH INTERMITTENT SUBCUTANEOUS HEPARIN IN THE INITIAL TREATMENT OF PROXIMAL-VEIN THROMBOSIS [J].
HULL, RD ;
RASKOB, GE ;
HIRSH, J ;
JAY, RM ;
LECLERC, JR ;
GEERTS, WH ;
ROSENBLOOM, D ;
SACKETT, DL ;
ANDERSON, C ;
HARRISON, L ;
GENT, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (18) :1109-1114
[8]  
Kitchen S, 1996, THROMB HAEMOSTASIS, V75, P734
[9]  
KOVACS MJ, 1996, LAB HEMATOLOGY, V2, P111
[10]   A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis [J].
Levine, M ;
Gent, M ;
Hirsh, J ;
Leclerc, J ;
Anderson, D ;
Weitz, J ;
Ginsberg, J ;
Turpie, AG ;
Demers, C ;
Kovacs, M ;
Geerts, W ;
Kassis, J ;
Desjardins, L ;
Cusson, J ;
Cruickshank, M ;
Powers, P ;
Brien, W ;
Haley, S ;
Willan, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (11) :677-681